High hopes and valuations set the tone for biopharma in 2021

10 December 2020

COVID-19 will continue to be a defining issue for pharma and biotech companies in 2021, but overall, the sector will start the year from a position of strength, according to the Evaluate Vantage 2021 Preview, published today.

Sales of COVID-19 vaccines are expected to reach between $10-15 billion next year, and for now Moderna’s (Nasdaq: MRNA) mRNA-1237 is the favored candidate among equity analysts, despite BioNTech (Nasdaq: BNTX) and Pfizer’s (NYSE: PFE) first mover advantage.

With many leading COVID-19 projects due to yield data next year, it should become clearer which companies will deliver clinically and commercially successful pandemic products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK